Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Myelodysplastic syndromes (MDS) * International Prognostic Scoring System (IPSS) score ≥ intermediate-2 * Chronic myelomonocytic leukemia * Acute myeloid leukemia arising from MDS * Must have failed or are ineligible for or intolerant to treatment with azacitidine * Patients with normal marrow cytogenetics or an isolated 5q- abnormality must have failed or are ineligible for or intolerant to treatment with lenalidomide * Patients who are HLA-DR15-positive must have failed or are ineligible for pharmacologic immunosuppression (e.g., anti-thymocyte globulin, cyclosporine, steroids) * No presence of cytotoxic antibodies against donor lymphocytes * No HLA-identical donor available OR ineligible for HLA-identical allogeneic bone marrow transplantation * HLA partially mismatched (haploidentical) related donor available * First-degree related donor, including half-siblings or first cousins * Inherited recombinant haplotype from parents allowed if donor shares ≥ 1 HLA antigen at each of the HLA-A, -B, and DR loci PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100% * Bilirubin \< 3.0 mg/dL * AST and ALT ≤ 4 times upper limit of normal * Creatinine \< 3.0 mg/dL * LVEF \> 35% PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from prior therapy * No prior transfusions from donor * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy * No other concurrent investigational drugs